Health Care & Life Sciences » Pharmaceuticals | Moleculin Biotech Inc.

Moleculin Biotech Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2015
2016
2017
2018
Cash & Short Term Investments
28.10
5,007.20
7,714.00
7,134
Other Current Assets
-
215.10
588.00
840
Total Current Assets
28.10
5,222.30
8,302.00
7,974
Net Property, Plant & Equipment
-
23.10
33.00
463
Long-Term Note Receivable
3.00
-
-
-
Intangible Assets
-
11,147.50
11,148.00
11,148
Total Assets
31.10
16,392.90
19,483.00
19,585
ST Debt & Current Portion LT Debt
-
296.40
-
Accounts Payable
-
-
810.00
Other Current Liabilities
322.80
1,048.70
1,405.00
Total Current Liabilities
322.80
1,345.10
2,215.00
Long-Term Debt
450.00
-
-
Other Liabilities
-
87.50
150.00
Total Liabilities
772.80
1,432.60
2,365.00
Common Equity (Total)
741.70
14,960.40
17,118.00
Total Shareholders' Equity
741.70
14,960.40
17,118.00
Total Equity
741.70
14,960.40
17,118.00
Liabilities & Shareholders' Equity
31.10
16,392.90
19,483.00

About Moleculin Biotech

View Profile
Address
5300 Memorial Drive
Houston Texas 77007
United States
Employees -
Website http://www.moleculin.com
Updated 07/08/2019
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company, which focuses on the development of oncology drug candidates. Its Annamycin product candidate helps in the treatment of relapsed or refractory acute myeloid leukemia. The company's preclinical small molecule portfolios focus on the modulation of hard-to-target tumor cell signaling mechanisms and the metabolism of tumors.